MGC Pharmaceuticals has added another notch to its belt after chalking up its 100th patient that has either been prescribed for or is being processed to receive prescriptions of its medical cannabis-based pharmaceutical products in Australia.
A bulk shipment of MGC’s pharmaceutical products is currently on its way to Australia with Tetra Health, an organisation that helps medical professionals and patients obtain safe access to medicinal cannabis products also recently adding MGC’s products to their product range.
Tetra Health will purchase the products from Health House for distribution to its network of pharmacies, prescribing physicians and partnered clinics.
MGC has permission from Australia’s Therapeutic Goods Administration to import its medicinal cannabis-based products for supply for use in either a clinical trial or under the Special Access Scheme.
The Special Access Scheme allows health practitioners to access therapeutic goods that are not in the Australian Register of Therapeutic Goods for